Aethlon Medical Successfully Closes Private Placement with Gross Proceeds of $3.3 Million

Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement

Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage medical therapeutic company, has disclosed its plans to initiate a private placement that will secure approximately $3.3 million in gross proceeds. This funding is a testament to the ongoing confidence in Aethlon's innovative solutions for tackling cancer and severe infectious diseases.

Details of the Private Placement

On December 5, 2025, Aethlon Medical entered a securities purchase agreement with a single institutional investor. This agreement encompasses the purchase of 595,897 shares of common stock or pre-funded warrants, alongside warrants allowing for the purchase of up to 1,042,820 additional shares of common stock. The pricing for this offering aligns with the current market under Nasdaq regulations. Each combined share and accompanying warrant is priced at $4.03, with the warrants being exercisable upon shareholder approval for five and a half years following that approval.

Additionally, Aethlon has negotiated a warrant inducement agreement with this institutional investor. This includes the adjustment of existing warrants issued in March and September 2025 to a lowered exercise price of $4.03. In exchange for immediate execution of these warrants, the company will issue unregistered warrants for an additional 368,471 shares.

Projected Use of Funds

The proceeds from this private placement will be pivotal as Aethlon Medical aims to enhance the development and potential market introduction of its Hemopurifier® technology. This device is designed to selectively eliminate pathogenic targets from biological fluids, addressing significant unmet needs in oncology and the treatment of infectious diseases. With these funds, Aethlon is better positioned to drive its clinical trials, which are essential in demonstrating the efficacy and safety of the Hemopurifier in treating conditions such as cancer and chronic infections.

This round of funding is expected to close approximately on December 8, 2025, contingent upon certain customary closing conditions. Maxim Group LLC is serving as the sole placement agent for this financial endeavor, ensuring that the company fulfills its obligations while maximizing investor relations.

Future Outlook

Aethlon Medical's recent activities signify a crucial step in its strategic plan to advance its business objectives and solidify its standing in the medical device market. The company recognizes the importance of bolstering its financial health to facilitate its roadmap toward innovative cancer therapies, particularly at a time when financial resources can accelerate research and therapeutic introductions in oncology.

Aethlon has also committed to filing a registration statement with the Securities and Exchange Commission regarding the resale of the securities from this placement. This move illustrates a commitment to compliance and to addressing potential investor queries regarding the availability and legality of their investment in the company.

With a promising trajectory and a solid financial backing from this private placement, Aethlon Medical eyes a future where it can drastically change the landscape of cancer treatment through its pioneering Hemopurifier technology. Investors and stakeholders will be keenly monitoring Aethlon's advancements as the company works toward realizing its primary goal of delivering innovative care solutions.

For further information regarding Aethlon Medical’s offerings and updates, visit AethlonMedical.com and follow their updates on LinkedIn.

About Aethlon Medical, Inc.

Headquartered in San Diego, California, Aethlon Medical is focused on addressing unfulfilled needs in oncology and infectious disease patient care. Its goal is to advance the Hemopurifier, utilizing sophisticated technologies intended to improve patient outcomes by efficiently targeting disease-causing agents in the bloodstream.